Target Information

Target General Infomation
Target ID
T82266
Former ID
TTDS00160
Target Name
Voltage-dependent L-type calcium channel
Synonyms
L-type Ca(2+) channel; L-type Ca2+ channel; L-type voltage-dependent Ca(2+) channel
Target Type
Successful
Disease Gastric motility disorder [ICD10: K22.4]
High blood pressure [ICD9: 401; ICD10: I10-I16]
Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10: A09, K58, K59.1]
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89]
BioChemical Class
Voltage-gated ion channel
Target Validation
T82266
Drugs and Mode of Action
Drug(s) Otilonium bromide Drug Info Approved Gastric motility disorder [551871]
Cilnidipine Drug Info Phase 3 High blood pressure [524770], [542719]
Pinaverium bromide Drug Info Phase 3 Irritable bowel syndrome [536224]
Methoxyverapamil Drug Info Phase 2 Discovery agent [522660]
Blocker Ajinomoto 1 Drug Info [537324]
Ajinomoto 2 Drug Info [537324]
Ajinomoto 3 Drug Info [537324]
Cilnidipine Drug Info [534852], [535452]
Desmethoxyverapamil Drug Info [536621], [538026]
Dihydropyridines Drug Info [534852]
Euro-Celtique 1 Drug Info [537324]
Euro-Celtique 2 Drug Info [537324]
Euro-Celtique 3 Drug Info [537324]
Euro-Celtique 4 Drug Info [537324]
Methoxyverapamil Drug Info [536621], [538026]
Neuromed 2 Drug Info [537324]
Neuromed 5 Drug Info [537324]
Ono 1 Drug Info [537324]
Ono 2 Drug Info [537324]
Ono 3 Drug Info [537324]
Otilonium bromide Drug Info [536224]
Parke-Davis 1 Drug Info [537324]
Parke-Davis 9 Drug Info [537324]
PD173212 Drug Info [537324]
PD176078 Drug Info [537324]
Pinaverium bromide Drug Info [536224]
SQ32,910 Drug Info [538026]
Activator Bay K 8644 Drug Info [538026]
S 202 791 Drug Info [538026]
References
Ref 522660ClinicalTrials.gov (NCT00896428) Effects of Gallopamil in Severe Asthma. U.S. National Institutes of Health.
Ref 524770ClinicalTrials.gov (NCT02145104) Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension. U.S. National Institutes of Health.
Ref 536224Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
Ref 542719(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7767).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 534852Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med. 1999 May;3(5):455-66.
Ref 535452N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
Ref 536224Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
Ref 536621Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
Ref 537324Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
Ref 538026Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.